JPND A Pilote Initiative on Combating Neurodegenerative Diseases, in particular Alzheimers disease

1
Towards Joint Programming in Research
JPND A Pilote Initiative on Combating
Neurodegenerative Diseases, in particular
Alzheimers disease
Prof. Philippe Amouyel National Foundation for
Alzheimers disease and related disorders
2
Towards Joint Programming in Research
1. A shared vision
2. A strategic research agenda
3. A management structure
4. A work plan
3
222 Participants

• Albania
• Belgium
• Czech Republic
• Denmark
• Estonia
• Finland
• France
• Germany
• Greece
• Hungary
• Ireland
• Italy

• Luxemburg
• The Netherlands
• Norway
• Poland
• Portugal
• Slovak Republic
• Slovenia
• Spain
• Sweden
• Switzerland
• Turkey
• United Kingdom

4
Management Structure

• Representatives able to take strategic decisions
  with sufficient authority to commit funds at a
  national level
• Ex A member of a research ministry, the director
  or senior executive of a research agency or a
  national council (e.g. Inserm for France, MRC for
  UK.) or any other representative
• On a voluntary basis
• Open to new participants
• Term of reference

5
The Management Board

• The Management Board meetings
• 18th June 2009
• 6th October 2009
• 13th November 2009
• Elections
• President Philippe Amouyel, France
• Vice President Maria Wästfelt, Sweden
• Executive board Adriana Maggi, Italy Enda
  Connolly, Ireland Eckhart Curtius, Germany
• The MB adopted
• The Term of Reference
• The SAB composition
• The Work Plan

6
The Scientific Advisory Board

• A Scientific Advisory Board proposal has been
  prepared by an ad hoc committee from the MB
  including Spain, Germany, Poland, France, Italy,
  Slovak Republic
• Each member had to provide 6 names from its own
  country and 6 from abroad
• 4 in basic research
• 4 in clinical research
• 4 in health care research
• A short list of 48 names was prepared by the ad
  hoc committee based on excellence
• The Executive board prepared a list of 15
  scientists who will be contacted

7
Work Plan

• The MB decided to answer to the Coordination
  Action in support of the implementation of a
  Joint programming Initiative for combating
  Neurodegenerative Diseases, in particular
  Alzheimers disease (HEALTH-2010.4.2-8)
  JUMPAHEAD
• An ad hoc writing group was set including
  Germany, Ireland, United Kingdom, The
  Netherlands, France
• Logistic help of Inserm-transfert (France)
• Meetings
• London, MRC, 24th September 2009
• London, MRC, 6th November 2009
• Paris, Inserm, 12th November 2009
• Paris, Inserm, 13th November 2009

8
Objectives

• Mapping of National and European research
  programmes
• Definition of strategic and scientific priorities
  that would benefit from coordination at the
  European level
• Definition of framework conditions to implement
  the SRA, i.e. political, legal, regulatory and
  financial arrangements
• Implementation of joint and coordinated research
  activities responsive to stakeholder interests
• Engagement of stakeholders through a
  communication plan to ensure the ultimate
  translation of research outputs into practice and
  policy
• Evaluation and monitoring of the joint activities

9
WP1-Management Coordination

• WP leader Inserm (France)
• Actions
• supports the leadership of the SC, EB and MB in
  guiding, directing and managing the JPND
• sets the pace of the entire JUMPAHEAD and of each
  WP,
• ensures that all decisions taken by the governing
  bodies (SC and MB) are appropriately implemented,
• guarantees the necessary flow of information
  among all participants of JUMPAHEAD as well as of
  the JPND,
• assigns and distributes the necessary resources
  to individual participants,
• organizes the SAB, MB, EB and SC meetings,
• prepares all the documentation necessary to
  inform the European Commission of the progress
  made by JUMPAHEAD.

10
WP2-Development of the Strategic Research Agenda

• WP leader MRC (United Kingdom), MIUR (Italy)
• Actions
• develop a Strategic Research Agenda (SRA)
• utilise the SAB to generate an overview of
  current research on neurodegenerative disorders
  within Europe
• Identify gaps and opportunities, and develop
  recommendations for the key research priorities
  and objectives
• The MB will further develop these recommendations
  into a SRA that will provide a framework for
  effectively harnessing the European research
  effort to improve prevention, diagnosis,
  treatment and patient care for these incurable
  and debilitating conditions.

11
WP3-Implementation of the Strategic Research
Agenda

• WP leader BMBF-PTDLR (Germany), TUBITAK
  (Turkey)
• Actions
• achieve the objectives of the JPND initiative by
  the implementation of the SRA
• provide a framework of opportunities, open to any
  country of JPND willing to participate in joint
  actions
• establish priorities based on the perspective of
  the funding organizations
• specify the actions, instruments and resources
  available for its implementation
• The MB will seek to implement the SRA in the most
  effective manner, either by utilising or adapting
  existing instruments and initiatives or by
  launching new initiatives such as joint
  trans-national calls for proposals.

12
WP4-Communication and Dissemination

• WP leader HRB (Ireland)
• Actions
• define a communication plan for engaging
  effectively with stakeholders
• execute this plan during the coordination action.
  In close consultation with the MB of JPND, the
• Identify the appropriate group of key
  stakeholders in the individual participating
  member states of the JPND
• develop the optimum modalities for the effective
  communication and dissemination of JPND
  information, developments and activities
• By supporting key stakeholders with appropriate
  information, the WP will aim to maximize both the
  support for the JPND and the involvement of
  participating member states in the collaborative
  initiatives.

13
WP5-Framework for monitoring and evaluation of
the JPND

• WP leader ZonMW (The Netherlands)
• Actions
• monitor and evaluate the merits and benefits of
  this way of conducting research and its impact
• enable the assessment of the impact of JPND on
  neurodegenerative disease research and its
  outcome
• evaluate the level of success in achieving the
  objectives of pooling national expertise and
  resources and establishing robust collaborations
  among participating states
• develop short, medium and long term measures and
  indicators that
• improve the JPND initiative as it evolves
• provide innovative ideas on indicators of
  performance and have them accepted and shared by
  all the EU

14
Management
15
Next meetings

• EB meeting (1/month) 15th December 2009 (Paris)
• MB meeting March 2010 (The Netherlands)
• MB meeting June 2010 (Germany)
• MB meeting October 2010 (Switzerland)

A new initiative around research excellence
intended to offer a competitive and attractive
image of European research prosecuted for the
greatest benefit of Europes populations and
economies